GLP 1 News and Research

RSS

MR Solutions installs 3T PET-MR system at Western University’s ImPaKT facility

MR Solutions has installed a 3T PET-MR preclinical imaging system at Western University’s one of a kind ImPaKT Laboratory in Ontario.

From MR Solutions 5 Feb 2020

Penn researchers receive nearly $5 million to reduce opioid cravings

Opioid overdoses take the lives of tens of thousands of Americans annually. Two researchers from Penn State College of Medicine have received nearly $5 million from the National Institutes of Health to study whether an already-approved drug can be used to reduce cravings and prevent relapse in those struggling with opioid addiction.

9 Dec 2019

GLP-1 receptors could serve as targets for novel medications to treat opioid use disorder

Opioid use disorder and overdose deaths are a major public health crisis in the United States. While medication-assisted treatments for opioid use disorder exist, these treatments remain inadequate for many patients, resulting in a high rate of relapse following detoxification.

31 Oct 2019

Study explores distribution of new diabetes cases and specialist density in the U.S.

In the last five years, the landscape of type 2 diabetes treatment has changed dramatically. Two new classes of drugs -- SGLT2 inhibitors and GLP-1 receptor agonists -- have been shown to prevent some of the most serious diabetes complications, including heart and kidney conditions, in patients.

25 Oct 2019

Tecan to launch Fluent Gx Automation Workstation for use in regulated laboratories

Tecan’s range of advanced liquid handling solutions will soon be enhanced with the introduction of the new Fluent® Gx Automation Workstation, designed specifically to meet the stringent needs of clinical and regulated laboratories.

From Tecan 29 Aug 2019

New injection helps reduce body weight, glucose levels in patients with obesity

An injection has helped reduce body weight and glucose levels in patients with diabetes and obesity in four weeks.

6 Aug 2019

SGLT-2 inhibitors do not increase the risk of UTIs in diabetics, concludes study

A new study has shown that SGLT-2 inhibitors used in the treatment of type 2 diabetes do not increase the risk of UTIs over other anti-diabetic medications.

31 Jul 2019

FDA approves first non-insulin drug for treatment of pediatric patients with type 2 diabetes

The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes.

18 Jun 2019

Diabetes drug could help with smoking cessation

Phillip Robinson has gone from 10 cigarettes a day to one or two every other day after enrolling in a smoking cessation clinical trial launched by researchers at The University of Texas Health Science Center at Houston

30 Apr 2019

Study provides framework for developing Ebola virus therapeutic under FDA Animal Rule

The U.S. Army Medical Research Institute of Infectious Diseases today announced that, for the first time, the U.S. Food and Drug Administration has provided formal regulatory agreement for use of an animal model to support development of a drug candidate, remdesivir, for treating deadly Ebola virus infections.

29 Mar 2019

New Metrohm Eco Titrator makes titration simple, safe, and reliable

When something goes wrong in quality control, the reputation of the brand concerned is at stake. Better to exclude risks in the first place.

From Metrohm USA Inc. 15 Mar 2019

Bariatric surgery changes the way our body senses food

How bariatric surgery helps people with obesity and diabetes is related to changes in the way the gut senses food and nutrients after the operation, researchers report February 5 in the journal Cell Reports.

8 Feb 2019

The T2B Infrastructure Center for Respiratory Disease set to enter into the final phase

The Korea Institute of Toxicology (KIT·Chief Dr. Song, Chang-woo) National Center for Efficacy Evaluation of Respiratory Disease Product (NCER·Chief Dr. Lee, Kyu-hong) obtained on January 10 the final decision from the Ministry of Health and Welfare that the T2B Infrastructure Center for Respiratory Disease would enter into the final phase (second phase) with funding of 3 billion KRW over two years.

4 Feb 2019

Gut immune cells could be responsible for metabolism changes finds study

A new study has shown that the immune cells within the gut could be related to the rate of metabolism. The results of the new study titled, “Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease,” are published in the latest issue of the journal Nature.

31 Jan 2019

New bacterial species may help fight obesity and metabolic disorders

The MyNewGut project has discovered new bacterial species and strains in healthy people that seem to be effective against obesity, metabolic and mental disorders related to stress and obesity (e.g. depression).

17 Dec 2018

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex's entire infectious disease vaccine platform.

24 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

New research presented at the annual meeting of the European Association for the Study of Diabetes and published simultaneously in The Lancet Diabetes & Endocrinology shows how the glucose-lowering drug lixisenatide can slow or prevent damage to the kidneys in macro-albuminuric patients with type 2 diabetes mellitus and cardiovascular disease.

3 Oct 2018

Genetic score helps predict future major coronary events, shows study

Coronary artery disease (CAD) is the leading killer of people with type 2 diabetes, and it's not a secret killer.

28 Sep 2018

INTEGRA’s electronic pipettes simplify work in GLP environments

Which brand of pipette to use may not be your first consideration when designing your laboratory workflows and SOPs to follow good laboratory practice, but choosing the right pipette can make it much easier to achieve consistent results.

From INTEGRA Biosciences 28 Aug 2018